Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis
- 1 November 2014
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (11), 6767-6772
- https://doi.org/10.1128/aac.03569-14
Abstract
We used two established neutropenic murine models of pulmonary aspergillosis and mucormycosis to explore the association between the posaconazole area under the concentration-time curve (AUC)-to-MIC ratio (AUC/MIC) and treatment outcome. Posaconazole serum pharmacokinetics were verified in infected mice to ensure that the studied doses reflected human exposures with the oral suspension, delayed-release tablet, and intravenous formulations of posaconazole. Sinopulmonary infections were then induced in groups of neutropenic mice with Aspergillus fumigatus strain 293 (posaconazole MIC, 0.5 mg/liter) or Rhizopus oryzae strain 969 (posaconazole MIC, 2 mg/liter) and treated with escalating daily dosages of oral posaconazole, which was designed to achieve AUCs ranging from 1.10 to 392 mg · h/liter. After 5 days of treatment, lung fungal burden was analyzed by quantitative real-time PCR. The relationships of the total drug AUC/MIC and the treatment response were similar in both models, with 90% effective concentrations (EC 90 s) corresponding to an AUC/MIC threshold of 76 (95% confidence interval [CI], 46 to 102) for strain 293 versus 87 (95% CI, 66 to 101) for strain 969. Using a provisional AUC/MIC target of >100, these exposures correlated with minimum serum posaconazole concentrations ( C min s) of 1.25 mg/liter for strain 293 and 4.0 mg/liter for strain 969. The addition of deferasirox, but not liposomal amphotericin or caspofungin, improved the activity of a suboptimal posaconazole regimen (AUC/MIC, 33) in animals with pulmonary mucormycosis. However, no combination was as effective as the high-dose posaconazole monotherapy regimen (AUC/MIC, 184). Our analysis suggests that posaconazole pharmacodynamics are similar for A. fumigatus and R. oryzae when indexed to pathogen MICs.This publication has 30 references indexed in Scilit:
- Combination Therapy for Mucormycosis: Why, What, and How?Clinical Infectious Diseases, 2012
- Efficacy of Caspofungin in Neutropenic and Corticosteroid-Immunosuppressed Murine Models of Invasive Pulmonary MucormycosisAntimicrobial Agents and Chemotherapy, 2011
- Pharmacokinetics and Pharmacodynamics of Posaconazole for Invasive Pulmonary Aspergillosis: Clinical Implications for Antifungal TherapyThe Journal of Infectious Diseases, 2011
- In Vitro Activity and In Vivo Efficacy of Posaconazole in Treatment of Murine Infections by Different Isolates of the Aspergillus terreus ComplexAntimicrobial Agents and Chemotherapy, 2011
- In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibilityJournal of Antimicrobial Chemotherapy, 2010
- Comparative Pharmacodynamics of Amphotericin B Lipid Complex and Liposomal Amphotericin B in a Murine Model of Pulmonary MucormycosisAntimicrobial Agents and Chemotherapy, 2010
- Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated InfectionAntimicrobial Agents and Chemotherapy, 2009
- Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatmentCurrent Opinion in Infectious Diseases, 2008
- Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary AspergillosisAntimicrobial Agents and Chemotherapy, 2007
- Molecular Basis for Enhanced Activity of Posaconazole against Absidia corymbifera and Rhizopus oryzaeAntimicrobial Agents and Chemotherapy, 2006